Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

106.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,948
Open 106.98
Bid (Size) 105.40 (1)
Ask (Size) 106.00 (2)
Prev. Close 106.98
Today's Range 106.98 - 106.98
52wk Range 72.88 - 115.49
Shares Outstanding 2,531,374,696
Dividend Yield 2.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
 
Via Benzinga
Got $5,000? 3 Stocks to Hold for the Next 20 Years
Not every company is built to thrive -- or even survive -- for the long haul. These are. 
Via The Motley Fool

Performance

YTD
-3.74%
-3.74%
1 Month
-3.74%
-3.74%
3 Month
+7.63%
+7.63%
6 Month
+22.10%
+22.10%
1 Year
+30.59%
+30.59%

More News

Read More
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck & Co Earnings Preview
Via Benzinga
Checking In With Merck Stock Before Earnings
Via Talk Markets
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
Via InvestorPlace
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Via Talk Markets
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Will This Billion-Dollar Acquisition Be a Smart Move for Merck?
Via The Motley Fool
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
Via The Motley Fool
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
From Merck & Co., Inc.
Via Business Wire
How I'd Invest $50,000 for Retirement If I Had to Start From Scratch
Via The Motley Fool
Earn Dividends Every Month With These 3 Stocks
Via The Motley Fool
My Biggest Winners Of 2022
Via Talk Markets
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
From Merck & Co., Inc.
Via Business Wire
Want to Collect a Dividend Every Month? Buy These 3 High-Yielding Stocks
Via The Motley Fool
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.